- Home
- WDI vs CBLL Comparison
WDI vs CBLL Comparison
Compare WDI & CBLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | WDI | CBLL |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | N/A | 280 |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 703.9M | 750.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WDI | CBLL |
|---|---|---|
| Price | $13.60 | $16.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $23.20 |
| AVG Volume (30 Days) | 165.6K | ★ 275.9K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 11.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $29.57 |
| Revenue Next Year | N/A | $28.44 |
| P/E Ratio | $12.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.91 | $10.85 |
| 52 Week High | $15.28 | $24.33 |
Technical Indicators
Market Signals| Indicator | WDI | CBLL |
|---|---|---|
| Relative Strength Index (RSI) | 42.88 | 33.12 |
| Support Level | $13.60 | $11.17 |
| Resistance Level | $13.77 | $20.25 |
| Average True Range (ATR) | 0.21 | 1.07 |
| MACD | -0.04 | -0.44 |
| Stochastic Oscillator | 16.98 | 18.09 |
Price Performance
Historical ComparisonAbout WDI Western Asset Diversified Income Fund of Beneficial Interest
Western Asset Diversified Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income. As a secondary investment objective, the Fund will seek capital appreciation. The fund seeks to achieve its investment objectives by investing, under normal market conditions, across fixed income sectors and securities in seeking to deliver a well-diversified portfolio.
About CBLL CeriBell Inc.
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.